Loading...

Affimed N.V.

0HL9.LLSE
Healthcare
Medical - Pharmaceuticals
£0.04
£-0.00(-0.27%)

Affimed N.V. (0HL9.L) Stock Overview

Explore Affimed N.V.’s financial performance, market position, analyst ratings, and future outlook.

Meyka AI Score

B

Score: 61.3/100

Key Financials

Market Cap639.6K
P/E Ratio-0.04
EPS (TTM)$-0.66
ROE-1.94%
Fundamental Analysis

AI Price Forecasts

1 Week$-0.34
1 Month$-1.33
3 Months$2.17
1 Year Target$0.00

0HL9.L Stock Analysis & Investment Overview

Our comprehensive AI-powered analysis of Affimed N.V. (0HL9.L) provides investors with deep insights into the stock's performance, growth potential, and market positioning. With a Meyka AI Score of B, this stock demonstrates moderate investment characteristics based on our advanced machine learning models.

The current technical analysis reveals key indicators including an RSI of 32.62, suggesting the stock is in a neutral condition. Our forecasting models predict significant price movements, with a 12-month target of $0.00.

Key financial metrics showcase the company's fundamental strength, including a P/E ratio of -0.04 and a market capitalization of 639.6K. These metrics, combined with our AI analysis, provide a comprehensive view for both institutional and retail investors.

Technical Indicators

32.62RSI (14)
-0.04MACD
9.48ADX
Stats data is not available for 0HL9.LStats details for 0HL9.L are currently unavailable. We're actively monitoring for updates and will publish them as soon as they’re released. Please check back again shortly.
Analyst Recommendations data is not available for 0HL9.LAnalyst Recommendations details for 0HL9.L are currently unavailable. We're actively monitoring for updates and will publish them as soon as they’re released. Please check back again shortly.

Company Profile

Affimed N.V., a clinical-stage biopharmaceutical company, focuses on discovering and developing cancer immunotherapies in the United States, Germany, and rest of Europe. Its lead product candidate is AFM13, which has completed Phase II clinical study for peripheral T-cell lymphoma; in Phase IIa clinical trial for CD30-positive lymphoma; and in Phase I clinical trial for hodgkin lymphoma. The company is also developing AFM24, a tetravalent, bispecific epidermal growth factor receptor, and CD16A-binding innate cell engager, which is in Phase IIa clinical trial for the treatment of advanced cancers; AFM28, an innate cell engager (ICE), which is in preclinical development to treat acute myeloid leukemia; and AFM32, an ICE candidate that is in preclinical development for the treatment of solid tumors. Affimed N.V. has collaboration agreements with The University of Texas MD Anderson Cancer Center; Genentech, Inc.; and Roivant Sciences Ltd., as well as research funding agreement with The Leukemia & Lymphoma Society. The company was formerly known as Affimed Therapeutics B.V. and changed its name to Affimed N.V. in October 2014. Affimed N.V. was founded in 2000 and is headquartered in Heidelberg, Germany.

CEO

Shawn M. Leland Pharm.D.,

Employees

76

Headquarters

Technologiepark, Mannheim

Founded

2018

Frequently Asked Questions

;